Edition:
United States

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

134.25USD
21 Feb 2018
Change (% chg)

$-0.07 (-0.05%)
Prev Close
$134.32
Open
$134.32
Day's High
$136.90
Day's Low
$134.25
Volume
195,301
Avg. Vol
368,128
52-wk High
$138.40
52-wk Low
$89.25

Chart for

About

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan... (more)

Overall

Beta: 0.56
Market Cap(Mil.): $28,424.78
Shares Outstanding(Mil.): 211.62
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.43 16.73
EPS (TTM): -- -- --
ROI: -- 9.70 35.60
ROE: -- 14.29 17.23

BRIEF-Edwards Says Its Self-Expanding Transcatheter Heart Valve Receives CE Mark

* GOT CE MARK FOR SELF-EXPANDING CENTERA VALVE FOR SEVERE, SYMPTOMATIC AORTIC STENOSIS PATIENTS AT HIGH RISK OF OPEN-HEART SURGERY

Feb 15 2018

BRIEF-Edwards Lifesciences Reports Qtrly Adj EPS of $0.94

* EDWARDS LIFESCIENCES QTRLY EARNINGS PER SHARE $0.17; QTRLY ADJUSTED EARNINGS PER SHARE $0.94

Feb 01 2018

BRIEF-Edwards Lifesciences Corp Acquires Harpoon Medical

* EDWARDS LIFESCIENCES CORP - EDWARDS PAID $100 MILLION IN CASH FOR HARPOON AT CLOSING ON DEC. 1

Dec 06 2017

Edwards results fall short of Street estimates; shares tumble

Edwards Lifesciences Corp on Tuesday reported slightly lower-than-expected third-quarter profit and revenue and saw a dip in sales of its critically important transcatheter heart valves from the prior quarter, although they grew about 17 percent from a year earlier.

Oct 24 2017

UPDATE 1-Edwards results fall short of Street estimates; shares tumble

Oct 24 Edwards Lifesciences Corp on Tuesday reported slightly lower-than-expected third-quarter profit and revenue and saw a dip in sales of its critically important transcatheter heart valves from the prior quarter, although they grew about 17 percent from a year earlier.

Oct 24 2017

Edwards 3rd-quarter results short of Street estimates; shares fall

Oct 24 Edwards Lifesciences Corp on Tuesday reported slightly lower-than-expected third-quarter profit and revenue and saw a dip in sales of its critically important transcatheter heart valves from the prior quarter, although they grew about 17 percent from a year earlier.

Oct 24 2017

Neovasc loses appeal of $112 million heart valve trade secrets award

A federal appeals court on Friday upheld an almost $112 million win for Edwards Lifesciences Corp, which accused rival medical device company Neovasc Inc of misappropriating its heart valve replacement technology.

Sep 01 2017

Earnings vs. Estimates